Trevi Therapeutics (TRVI) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Trevi Therapeutics (TRVI) right now is Haduvio Phase 3 in IPF-related chronic cough: The lead program advanced into Phase 3 in early 2026 after positive Phase 2b CORAL data and overall alignment with the FDA at an End-of-Phase 2 meeting. Product revenue (TTM) is ~$0 (clinical stage, no approved products). If that keeps playing out, the setup is favourable; the risk to it is trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. No one can predict where TRVI trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Trevi Therapeutics (TRVI) higher?
1. Haduvio Phase 3 in IPF-related chronic cough.
The lead program advanced into Phase 3 in early 2026 after positive Phase 2b CORAL data and overall alignment with the FDA at an End-of-Phase 2 meeting. IPF-related chronic cough has no approved therapy, so a successful Phase 3 followed by approval would give Trevi a first-in-class product. This readout is the single most important catalyst for the stock.
2. Refractory chronic cough expansion.
Trevi is also running a Phase 2b trial of Haduvio in refractory chronic cough (RCC), a far larger patient population, after its Phase 2a RIVER trial met its primary endpoint in 2025. RCC is a market that has frustrated larger competitors, and success here would materially widen Haduvio's commercial opportunity beyond the smaller IPF indication.
3. Differentiated mechanism.
Haduvio's kappa-agonist, mu-antagonist (KAMA) mechanism is distinct from the P2X3 antagonists that dominate rival chronic cough pipelines. Management highlights that Haduvio has shown statistically significant cough reductions across both IPF and RCC patients, a breadth its P2X3 peers have not consistently matched, which is the core of the differentiation thesis.
4. Funded runway into 2030.
An April 2026 offering added roughly $162 million in net proceeds on top of about $171.8 million in cash at the end of Q1 2026, giving a projected runway into 2030. That funding is meant to carry the company through its planned IPF and RCC trials and potential FDA approval without an imminent need to raise more capital, reducing near-term dilution pressure.
What could weigh on TRVI?
Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Finally, the ~$2 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline.
Where TRVI trades today
A forecast starts from where the stock actually is. These are TRVI's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for TRVI as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a TRVI forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the TRVI guide and whether TRVI is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the TRVI outlook
The bottom line: what is driving Trevi Therapeutics (TRVI) is Haduvio Phase 3 in IPF-related chronic cough, with product revenue (ttm) at ~$0 (clinical stage, no approved products). If that keeps playing out the setup is favourable; the risk is trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. No one can predict the price, so treat any TRVI forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around TRVI with Walnut
Use Trevi Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Trevi Therapeutics (TRVI)?
+
No one can reliably predict where TRVI will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Trevi Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive TRVI higher?
+
The main growth drivers are Haduvio Phase 3 in IPF-related chronic cough; Refractory chronic cough expansion; Differentiated mechanism. Whether they play out is the real question, not a guaranteed path.
What are the risks to TRVI?
+
Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Finally, the ~$2 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline.
Will TRVI stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Trevi Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is TRVI a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the TRVI "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.